Stay updated on Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed. Additionally, a note regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    0.8%
    Check dated 2025-07-04T04:08:11.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.6%
    Check dated 2025-06-19T20:00:39.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:20:30.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:08:42.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:24:33.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new phase II trial evaluating the anti-tumor activity of pembrolizumab and tamoxifen in patients with hormone receptor positive, HER2 negative metastatic breast cancer. Key details about the study's focus on immune checkpoint inhibitors and the involvement of specific investigators have been added.
    Difference
    55%
    Check dated 2025-04-16T11:09:17.000Z thumbnail image

Stay in the know with updates to Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page.